Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

#For researchers

Written for academic and pharma-industry researchers; assumes domain literacy.

Explainer

Stapled semaglutide variants, explained

A new chemistry paper built stapled variants of a semaglutide fragment that last longer in serum; here is what that does and does not show.

12 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Rat Achilles study: BPC-157 and TB-500

A 32-rat Achilles repair study found TB-500 improved load to failure and tendon histology at four weeks. BPC-157 did not reach significance.

3 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Peptides for tendon recovery: the evidence

BPC-157 and TB-500 have promising animal data for tendon and ligament repair, but almost no human trial evidence. Here is how to weight it.

31 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Tendon recovery peptides: evidence grade

BPC-157 has consistent animal tendon data. TB-500 has one human ophthalmic RCT. Neither has an RCT for tendons or ligaments. An honest evidence grade.

31 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Methodology

GH-axis peptides: weighing the evidence

Tesamorelin, CJC-1295 and ipamorelin sit on three different rungs of the evidence ladder. Here is how to weight what each one actually shows.

30 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Methodology

GH-axis peptides: grading the evidence

Tesamorelin has two Phase 3 RCTs and FDA approval. CJC-1295 has two early-phase studies. Ipamorelin has one PK study and a negative Phase 2.

30 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Peptides for injury recovery: the evidence

BPC-157 and TB-500 are the most-asked injury-recovery peptides. Here is what is trial-supported, what is animal-only, and what is just anecdote.

30 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Peptide longevity: what the evidence shows

What trial data supports for peptides marketed for longevity: from GLP-1 cardiovascular outcomes to preclinical Epitalon and GHK-Cu research.

30 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Methodology

Peptides for muscle gain: the evidence

Ipamorelin and CJC-1295 lead the muscle-gain peptide conversation. Here is how their evidence actually ranks, from human pharmacology to mouse data to anecdote.

30 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Sexual-function peptides: the evidence

Only one sexual-function peptide, bremelanotide (Vyleesi), has real trial support, and only for one use. Here is how to weigh the evidence tier by tier.

30 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Methodology

Peptides for sleep: the evidence grade

MK-677 has a small controlled trial showing improved sleep architecture. Ipamorelin and CJC-1295 raise GH, but their sleep effects remain untested in humans.

30 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Methodology

Longevity peptides: weighing the evidence

Tesamorelin and ipamorelin get sold as anti-aging tools. Here is what the trial evidence actually supports, and the longevity gap it leaves.

30 Jul 2026 · PeptideMethods Editorial Team · 4 min read